GGrantIndex
← Search

PILOT--GENITOURINARY CANCER

$0P30FY2001CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07456436Trial NCT07339254Trial NCT07332312Trial NCT07312162Trial NCT07306338Trial NCT07279571Trial NCT07276048Trial NCT07259304Trial NCT07229443Trial NCT07186699Trial NCT07162194Trial NCT07082257Trial NCT07076147Trial NCT06500169Trial NCT06422455Trial NCT06420219Trial NCT06374251Trial NCT06338657Trial NCT06336928Trial NCT06336902Trial NCT06297265Trial NCT06191575Trial NCT06171607Trial NCT06132087Trial NCT06128525Trial NCT06067295Trial NCT06063928Trial NCT06063486Trial NCT06060873Trial NCT05989828Trial NCT05791448Trial NCT05786664Trial NCT05516485Trial NCT05514990Trial NCT05462561Trial NCT05340309Trial NCT04981834Trial NCT04941430Trial NCT04927559Trial NCT04832763Trial NCT04830735Trial NCT04752267Trial NCT04387084Trial NCT04387071Trial NCT04373044Trial NCT04318028Trial NCT04315701Trial NCT04162678Trial NCT03971266Trial NCT03921047Trial NCT03858205Trial NCT03789773Trial NCT03739801Trial NCT03698162Trial NCT03657641Trial NCT03594448Trial NCT03576963Trial NCT03568292Trial NCT03568266Trial NCT03563651Trial NCT03563352Trial NCT03552796Trial NCT03537690Trial NCT03519984Trial NCT03514927Trial NCT03492801Trial NCT03485794Trial NCT03412370Trial NCT03408561Trial NCT03353896Trial NCT03348137Trial NCT03344211Trial NCT03330821Trial NCT03300609Trial NCT03300401Trial NCT03284346Trial NCT03267680Trial NCT03257761Trial NCT03238664Trial NCT03234556Trial NCT03207854Trial NCT03176979Trial NCT03146871Trial NCT03137706Trial NCT03120390Trial NCT03111823Trial NCT03098277Trial NCT03092856Trial NCT03091842Trial NCT03091816Trial NCT03091803Trial NCT03057639Trial NCT03049618Trial NCT03042897Trial NCT02978846Trial NCT02970617Trial NCT02970045Trial NCT02968680Trial NCT02967380Trial NCT02960308

Abstract

The Genitourinary (GU) Cancer Program is a multi-disciplinary program focused on the pathogenesis, diagnosis, prevention and treatment of genitourinary malignancies. While the emphasis on this Program has been and will continue to be on bladder and prostate cancers (the most common genitourinary malignancies), we are developing increasing emphasis in renal and testicular cancer as well. The scientific goal of the molecular aspects of genitourinary cancer progression and to translate discoveries into novel diagnostic and therapeutic strategies; (c) to examine the epidemiology of genitourinary cancer in order to develop hypotheses regarding possible causation, molecular etiology, and novel prevention strategies; and (d) to develop and test new surgical, chemotherapeutic, radiotherapeutic, biologic and combined modality approaches to the treatment of genitourinary cancer. These goals are being addressed through our considerable strengths in epidemiology, basic research, translational research, and clinical investigation. The GU Program which was newly proposed in the previous grant cycle, now contains 26 members from eight departments. The Program is supported by 29 peer-reviewed research projects (up from eight peer- reviewed research grants in the previous application) from 14 principal investigators. Funding totals are now over $4.7 million in direct costs annually, and a large proportion of the funded grants are multi- disciplinary. The GI Program is directly supported by the Cancer Center Core Facilities, including major involvement with Biostatistics and Cancer Research Informatics Core Facilities. The Cancer Center also fosters interaction in the GU Program through sponsorship of monthly meetings of the GU Group, GU focused Cancer Center Grand Rounds, and GU Retreats. Thus, the GU Program is an integral and well-integrated part of the USC/Norris Comprehensive Cancer Center.

View original record on NIH RePORTER →